JPND
The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has announced an €18 million transnational call for multinational research on novel imaging and brain stimulation methods and technologies for neurodegenerative diseases.
With neurodegenerative diseases on the rise and strongly linked to age, as many as 47 million people worldwide are estimated to be suffering from Alzheimer’s and related disorders today. This figure is expected to double every 20 years as the population ages. JPND was established in order to better coordinate research efforts across countries and disciplines to find causes more rapidly, develop cures and identify better ways to care for people with neurodegenerative diseases.
In recent years, major increases in the range and power of technologies across the basic, clinical and patient-centered domains of JPND have been seen. These include the use of imaging and analysis technologies, from Magnetic Resonance Imaging (MRI) to Position Emission Tomography (PET) to Molecular Imaging at both a molecular and a whole body imaging level, and the use of brain stimulation techniques such as Deep Brain Stimulation (DBS), Neuromodulation and Transcranial Magnetic Stimulation (TMS). Whilst techniques as such help to better understand, treat or diagnose neurodegenerative diseases, there is nevertheless a need to assess the potential of these approaches to deliver new and better treatment options for these debilitating diseases.
In this context, JPND is inviting multinational research teams to submit proposals for ambitious, innovative, multinational and multidisciplinary collaborative research projects aimed at the development of novel and the advanced use of existing cutting-edge imaging and brain stimulation technologies related to neurodegenerative diseases.
Professor Philippe Amouyel, University of Lille (France) and Chair of the JPND Management Board says: "The incredible progresses of brain imaging and brain stimulation during the last ten years, thanks to the development of new technologies, bioinformatics and artificial intelligence, offer new opportunities to better diagnose and alleviate the consequences of neurodegenerative diseases. For its 2020 transnational call, JPND has decided to support ambitious and innovative research projects that will take stock of these new approaches in a trans-disciplinary context. We hope that this highly competitive call will allow us to assess the potential of these approaches to deliver new and better treatment options.”
Proposals submitted under this call must focus on one or several of the following neurodegenerative diseases: Alzheimer’s disease and other dementias, Parkinson’s disease and PD-related disorders, Prion diseases, Motor neuron diseases, Spinocerebellar ataxia (SCA), Huntington’s disease, Spinal muscular atrophy (SMA).
In addition, proposals must focus on one or several of the following research areas:
- Imaging technologies
- Development of novel imaging technologies
- Improvements to the application of existing cutting-edge imaging technologies
- Brain stimulation techniques
- New or improved applications of both invasive and non invasive brain stimulation techniques for the diagnosis and treatment of neurodegenerative diseases
Pre-proposals must be submitted no later than 15:00h C.E.T. on March 6, 2020.
For more information about the call, please click here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005195/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom